Abstract 2253P
Background
RAS is the most commonly mutated oncogene in cancer, with KRAS mutated in ∼30% of non-small cell lung cancer (NSCLC). The most common KRAS mutation in lung-adenocarcinoma is KRAS codon 12 followed by 13. Newly developed drugs to target KRAS-G12C have highlighted the importance of studying the unique molecular and functional mechanisms of individual allelic subtypes.
Methods
We developed a doxycycline inducible panel of isogenic cell lines (MLE-12: alveolar type II cells) expressing flag-tagged KRAS WT or KRAS mutant: G12C, G12D, G13C and G13D. Cells were characterised in 3D using proliferation, viability, transformation and signalling assays. A panel of “RASless” mouse embryonic fibroblasts (MEFs) expressing KRAS WT, G12C, G12D and G13D were also evaluated. For clinical validation, we developed a clinical database (RAS-PM), to interrogate co-mutational frequencies and pathogenicity.
Results
Expression of KRAS WT, 12C and 12D in MLE-12 cells resulted in an increase in proliferation, compared to a decrease or plateau observed with KRAS 13C or 13D expression. Furthermore, there was increased viability in cells expressing KRAS codon 12 mutations compared to WT or codon 13 mutations. All KRAS mutant MLE-12 cells expressed markers of transformation (EPCAM and CD44), including codon 13 mutants. In addition, there were differences in activation of AKT signalling between KRAS G12D and G13D expressing cells. Therapeutic vulnerabilities to a novel active-state selective RAS (‘ON’) inhibitor were assessed, where the most and least sensitive cells were those expressing G12C or G12D, respectively. RAS-PM identified that KRAS G13D was more prevalent in NF1 mutant cancers vs. NF1 wildtype (NF1 MT: 6/24, 25%; vs. NF1 WT: 4/281, 1.4%; p<0.0001). Pathogenic NF1-mutations were identified in 5/6 (83%) of G13D/NF1 co-mutant cases.
Conclusions
Our findings highlight molecular and functional differences across the panel of KRAS mutations evaluated demonstrating differences in proliferation, viability, and signalling. These preclinical results indicate unique therapeutic vulnerabilities across allelic subgroups. RNA-sequencing and kinome profiling will allow us to further characterise these mutations in NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Revolution medicines.
Disclosure
C.R. Lindsay: Financial Interests, Institutional, Advisory Role: Amgen; Financial Interests, Institutional, Research Funding: Revolution Medicines. All other authors have declared no conflicts of interest.
Resources from the same session
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08